Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 4-Imidazolecarboxylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Imidazolecarboxylic Acid SCHEMBL27485308 | 1.00 | NPC1 (0.52) | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL317725 | 0.98 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL27315802 | 0.95 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL28085192 | 0.95 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL27484959 | 0.95 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL28747764 | 0.95 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL27473022 | 0.95 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL27760420 | 0.87 | TP53 (0.46) | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL17143063 | 0.87 | HRH3 (0.53) | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL10646188 | 0.86 | NPC1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1893941-A | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC (JP) | 2007-01-10 | — | — | CN | claimed |
| CN-1167680-C | fused ring compound and pharmaceutical use thereof | �ձ��̲ݲ�ҵ��ʽ���� | 2004-09-22 | — | — | CN | claimed |
| CN-1342145-A | fused ring compound and pharmaceutical use thereof | JAPAN TOBACCO INC (JP) | 2002-03-27 | — | — | CN | claimed |
| US-12128028-B2 | Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof | Metrion Biosciences Limited (GB) | 2024-10-29 | — | — | US | disclosed |
| CN-118638140-A | Oxo-substituted compounds | 住友制药株式会社 | 2024-09-13 | — | — | CN | disclosed |
| CN-112135830-B | Oxo-substituted compounds | 住友制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11066425-B1 | Oxo-substituted compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20210147448-A1 | OXO-SUBSTITUTED COMPOUND | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-3786168-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-03-03 | — | — | EP | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| CN-1623984-A | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC (JP) | 2005-06-08 | — | — | CN | disclosed |
| CN-1167680-C | fused ring compound and pharmaceutical use thereof | �ձ��̲ݲ�ҵ��ʽ���� | 2004-09-22 | — | — | CN | disclosed |
| CN-1342145-A | fused ring compound and pharmaceutical use thereof | JAPAN TOBACCO INC (JP) | 2002-03-27 | — | — | CN | disclosed |
| CN-1056140-C | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease | SANKYO CO (JP) | 2000-09-06 | — | — | CN | disclosed |
| CN-1027536-C | Process for producing 4,5,6,7-tetrahydrobenzimidazole derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1995-02-01 | — | — | CN | disclosed |
| CN-1095374-A | Biphenyl derivatives, their preparation and they are in the application for the treatment of hypertension and cardiac disease | SANKYO CO (JP) | 1994-11-23 | — | — | CN | disclosed |
| CN-1043706-A | 4,5,6,7-tetrahydrobenzene benzimidazole derivative preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1990-07-11 | — | — | CN | disclosed |
| EP-0275603-A1 | Tricyclic 1H-imidazole-5-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-07-27 | — | — | EP | disclosed |